Kite grabs a stem cell biology ‘breakthrough’ in race for off-the-shelf T cell therapies
Looking for an edge in the race to develop blockbuster off-the-shelf cell therapies to fight cancer, Kite Therapeutics has grabbed a license for new T cell tech from UCLA that the biotech believes can play a breakthrough role in the field of allogeneic drugs.
Kite’s rep in R&D has been based on the first generation of CAR-T drugs that extracts cells from patients and then customizes them with chimeric antigen receptors. Once infused back into patients, they’re designed to track down and eliminate cancer cells. And Kite has one of the most advanced programs now in a pivotal study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
